

WHAT IS CLAIMED IS:

1. Use of (R)-(+)-verapamil or a pharmaceutically acceptable salt thereof for manufacturing a medicament for the treatment of diabetes mellitus and/or disorders related to diabetes mellitus.
- 5 2. The use of claim 1, wherein the (R)-(+)-verapamil or a pharmaceutically acceptable salt thereof is in crystalline form.
3. The use of claim 2, wherein the (R)-(+)-verapamil exist in its hydrochloride salt.
4. The use of claim 1, wherein the medicament further comprises a blood
10 glucose reduction agent.
5. The use of claim 4, wherein the blood glucose reduction agent is insulin, an insulin analogue, biguanide, or α -glycosidase inhibitor.
6. The use of claim 5, wherein the insulin analogue is glargine, degludec or detemir.
- 15 7. The use of claim 5, wherein the biguanide is metformin, phenformin, or bufomin.
8. The use of claim 5, wherein the α -glycosidase inhibitor is acarbose, miglitose, or voglibose.
9. The use of claim 1, wherein the medicament is suitable for oral,
20 intravenous, intramuscular, subcutaneous, transmucosal, or intrarectal administration.
10. The use of claim 9, wherein the medicament for oral administration is provided as tablets, pills, granules, powders, solutions, suspensions, syrups or capsules.
- 25 11. The use of claim 9, wherein the medicament is administered in the amount of 15 to 1,000 mg/day.
12. The use of claim 11, wherein the medicament is administered in the amount of 25 to 800 mg/day.